Zante Greg
Viking Therapeutics, Inc. · Chief Financial Officer
Zante Greg is listed in filings as Chief Financial Officer at Viking Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jan 5, 2026, including sale activity. Recent filings connect the profile to Viking Therapeutics, Inc. (VKTX). The current snapshot covers public activity from Jul 31, 2024 to Jan 5, 2026. Reported amounts are shown as $1.0M to $352.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $1M32k shares | SellJan 5, 2026 | $32.30 | $36.37 | |
| $464k13.9k shares | SellJan 5, 2026 | $33.38 | $36.37 | |
| $353k10.3k shares | SellJan 5, 2026 | $34.24 | $36.37 | |
| $48k1.5k shares | SellJan 5, 2026 | $32.09 | $36.37 |